Act as a master negotiator who is acting as Lee Young in the following negotiation. Job…
- User
Act as a master negotiator who is acting as Lee Young in the following negotiation.
Job Terms Negotiation* Lee Young** and Purezza Pharmaceuticals*** Introduction The scenario for this simulation is a negotiation over the terms of a job offer from the Australian subsidiary of a multinational pharmaceutical company, Purezza Pharmaceuticals (Asia-Pacific) (PP). The recipient of the offer is Lee Young, a student nearing completion of his undergraduate studies. This background information introduces the principals involved, recaps their prior relationship, and presents a detailed summary of the terms of the offer that the firm has extended to the student. For the negotiation simulation, your tutor will assign you to the role of either Lee or Alex Reclutamento, representing PP in the hiring process. The role-play information that your tutor will then provide to you gives details about the specific interests, goals and objectives of your role character – as well as alternative options. Negotiations following job offers share many characteristics with other negotiation. Parties try to pursue their own interests but also prioritize relationship concerns by seeking areas of common ground. In other ways, however, negotiations over employment terms are distinctive because of the stakes involved. For the person offered the job, they involve the negotiation of one's personal circumstances, often with an “opponent” who is someone you will have to "live with" on a day-to- day basis for what could be a long time to come. As you plan for your negotiation, think about how this may affect how you would pursue your interests and goals when negotiating the terms and conditions of the job offered to you. Background Information Lee Young is a UNSW student in the final year of his five-year combined Bachelor of Science in Pharmacology and Bachelor of Commerce (International Business major). In 2017, he completed his BSc honours research year in Pharmacology (achieving First Class Honours) so the only courses left to complete this year are in his BCom. He has an offer (see Offer Letter, below) for full-time employment from Purezza Pharmaceuticals, and the deadline for accepting the offer is a little more than one week away. Lee spent last summer as an intern working at PP’s Macquarie Park, Sydney, regional headquarters. His boss during the internship was Alex Reclutamento. Alex heads the section marketing PP's blood-pressure and cholesterol-lowering drugs into North-East Asia and is the person at PP with whom Lee will negotiate the terms of the offer. Economic and Industry Conditions At the time of the job offer, many in the international pharmaceutical business were fearful of the fallout from the growing trade crisis between the USA and China, economic and political turbulence in Europe (including Italy) and deep economic crises affecting important parts of Latin America, including Brazil and Argentina. However, much of north-east Asia as well as Australia have, to date, largely avoided the worst effects of these trends. Indeed, the pharmaceutical industry has benefited through rising standards of living in many Asian economies. A longer-term trend is corporate merger and acquisition activity that has created a small number of enormous multinational corporations. It is largely these companies that carry on the hugely expensive research and development (R&D) leading to the commercialization of major, new “branded” products. At the same time, there is a growing market, in wealthy as well as less wealthy countries, for “generic” drugs produced by firms that take advantage of the lapsing (through time) of patents on well- known branded drugs. Generic drugs producers can manufacture at a fraction of the cost because they do not need to carry out the hugely expensive original R&D – including clinical trials – do not conduct the expensive patent securing/defence processes or engage in the original and expensive marketing that gets the branded product (and its composition) known to medical practitioners. There has been an 2 enormous increase in the diffusion of generic drugs to developing countries, particularly from low-cost production in countries like India. Company Background Purezza Pharmaceuticals (PP) emerged from the 1995 merger between an Italian firm, once part of a state-owned conglomerate, and a Swiss/Swedish company. Both had strong R&D traditions but suffered in the face of fierce competition from huge corporations whose greater R&D capacity and commercialization resources allowed them to stake leading positions in developing branded drugs. PP has since taken over two smaller, older Italian companies, an innovative German bio-technology company and a couple of companies each in Argentina and Brasil that specialize in generic drug production and sales. PP now has its headquarters just outside Milan and a dual listing on the Milan and Zurich stock exchanges. It has two research facilities in Italy, one in Switzerland, another in Germany, one in California and one in Sydney. It has production, packaging and distribution facilities in a number of countries in Europe, North and South America and in Australia. Its network of commercial offices is even more diffuse. Overall, PP has about 19,000 employees around the world, of whom about 2,700 are involved in R&D. Its research reach is even wider through collaborative arrangements and sponsorships at a number of universities across the globe, including UNSW in Sydney. Overall, this makes it a mid-tier, multinational “pharma” company, with particular market strengths in parts of Europe and in Latin America. Its current head-office senior management has strong ambitions for PP to achieve significant growth through expansion in the Asia Pacific region. The Sydney operations have expanded in recent years as a result of the decision, taken in Milan, to use Sydney as the initial base for major expansion into the Asia Pacific, starting with North-East Asia. In its present form, it has been based in Macquarie Park in northern Sydney since 1998 and has become an important part of PP’s global operations and an increasingly important strategic element. There are currently about 490 employees at the Macquarie Park operations, of whom 90 are working in R&D. Indeed, the company is a member of Medicines Australia, a body representing the innovative medicines industry in Australia. Total annual investment in PP’s Sydney operations is about AUS 40 million. Sales in Australia and New Zealand have been strong and the Sydney office has had fruitful co-marketing and sales arrangements with local firms in Singapore, Japan and Hong Kong. However, the real focus is now on developing a more substantial commercial presence in Japan, Taiwan, South Korea and China. Like PP in Europe, PP in Sydney prides itself on its reputation as an “employer of choice”. Its particular focus here includes a number of policy initiatives: a strong commitment to equality of opportunity in employment; special, free English language classes for those who might need them; support for employees’ career development both in Sydney and through access to overseas postings; provision of generous opportunities for further education and training; opportunities to shift within the company’s different divisions; competitive salaries; flexible working arrangements; and a range of benefits including enhanced superannuation (pension) benefits and company-subsidized child- care arrangements through three child care centres in the Macquarie Park area; six months fully- paid maternity leave (after a minimum 18 months’ employment); three weeks’ paid paternity leave; subsidized membership at a gym around the corner. Lee Young's Internship Experience at PP Lee worked at PP during the summer between his fourth and fifth years of his (5-year) combined degree program. He was fortunate to have secured an internship at PP because, with rising global economic uncertainty, many of the big “pharma” companies operating in Sydney have suspended their internship programs and curtailed graduate recruitment. It just so happened that, although PP was suffering commercially in Europe and Latin America, its early work in north-east Asia through 3 the Sydney operations had been showing real promise. This meant that it took on a small number of interns over summer 2017/2018, almost entirely people doing marketing and international business majors. It particularly wanted imminent graduates fluent in the main languages of its North East Asian target markets. Lee’s international business major was important for PP but more important was the direct, personal recommendation he received from Lee’s honours thesis supervisor, an eminent professor of pharmacology at UNSW, who also happens to have had a close, collaborative research relationship with PP for nearly a decade. The professor is now working on a major new PP-funded research project that Lee’s excellent honours thesis has contributed to in a minor way. This project will likely continue for a further 5 years and the professor was hoping that Lee would return to it through taking on further research work through a PhD thesis. Lee would love to continue working in research through a PhD program at UNSW but would prefer to do that while employed by a “pharma” company as this offers the prospects of much better job security. While the professor had hoped that Lee would do his summer internship in the company’s labs, the manager of PP’s internship program assigned Lee to the commercial side of the Sydney operations, in fact to Alex Reclutamento’s section. Lee and Alex got on well from the start and Lee fitted in with the close-knit teamwork that Alex had developed in her section. Alex Reclutamento began working at PP 17 years ago, when the company really began to expand its Sydney operations. Also a scientist by training, she has, however, chosen to pursue a career as a manager on the business side of the company. Alex is enormously capable professionally and charming and engaging interpersonally. People really like working with and for her, in part because she works so hard on their behalf. When she joined PP, she had the particular advantage of being bilingual in Italian and English due to her childhood years in Italy prior to migrating to Australia with her family. Her being bilingual and cross-culturally adept was important in PP’s original decision to hire her. At that time, PP’s local operations were still heavily staffed with Italian managers, some of whom had less than adequate English-language ability and limited familiarity with Australia. Alex rose quickly through the local PP ranks as operations expanded and she enjoyed successful postings abroad – in Italy and Argentina. A proven performer, Alex has increasingly been assigned to pivotal, vital roles within PP. Her task of managing expansion into North-Eastern Asia is vitally important for the whole of PP, not just for PP (Asia-Pacific). When he landed the summer internship, Lee expressed an interest in working in the R&D side. However, PP’s HRM people saw this as less important and relevant than exposure to the commercial side of the business. They thus assigned Lee to regional product management with Alex. The internship exposed Lee to senior management and different groups within the company. Indeed, Lee received accolades from senior local executives following his presentations on conditions and context in key target markets, likely modes of entry, and particular areas of regulatory compliance. The internship ended on a high note for the company and for Lee Young. PP (Asia- Pacific) used some of the work he prepared to prepare a promising business plan for a joint venture in Korea. And, Lee received a job offer letter from PP. The offer came from Alex Reclutamento's section, not from the R&D section that Lee was really hoping to join. While job assignments at PP can change frequently and senior management is very amenable to helping people transfer within the company, Lee is concerned that too much time spent away from research work will mean a deterioration in his research skills and greater difficulty in re-entering the world of scientific research. At the end of the summer, Alex assured Lee that if his interest truly lay with R&D, he would not have to spend too long in the commercial side before transferring over. Alex herself had performed well in her initial job assignment within PP, and subsequently found herself courted by executives from several different internal groups who wanted her on their teams. Although the permanent job offer was tendered back in late March after the conclusion of the internship, PP told Lee that the offer would remain available until August 2. The specific terms of the offer are shown in the offer letter. Now it is July 19, and Lee has arranged to speak with Alex to discuss the offer before making a decision. 4 Offer Letter Purezza Pharmaceuticals, 1-5 Research and Development Ave, Macquarie Park, NSW March 26, 2018 Lee Young 28 Studious Street, Kensington, NSW Dear Lee, On behalf of Purezza Pharmaceuticals (Asia-Pacific), I am delighted to confirm our offer to you of the position of Graduate Recruit. Your appointment will be effective December 3, 2018. The specifics of this offer are as follows: Position: Graduate Recruit, North-East Asian business development: blood pressure and cholesterol-lowering products. Starting salary will be 62,000 annually, paid fortnightly. There is the provision for annual salary increments – subject to your supervisor’s assessment of your performance – of up to $1,000, available at the end of each of the first two years of your employment with PP. Annual Bonus: An annual bonus may be available depending on employee performance and the employer’s judgement as to whether economic circumstances allow for the paying of bonuses. Superannuation: Company standard 12% employer contribution (cf. 9.5% current legal requirement). This is a non-negotiable entitlement. Benefits: Purezza Pharmaceuticals (Asia-Pacific) provides comprehensive and generous employment benefits to its employees. You will be entitled to all the benefits detailed in the applicable plan document in effect at the time you join the company. The Human Resources Department will send details on these benefits, along with specifics regarding paid sick leave, paid parental leave and paid annual holiday leave, under separate cover. This offer remains in force until August 2, 2018. If you choose to accept the offer, please sign and return a copy of this offer letter on or before that date. Should you have any questions, the appropriate point of contact is the hiring manager, Alex Reclutamento. We are impressed with your background and experience, and we look forward to having you join the Purezza Pharmaceuticals team in December.
ROLE INFORMATION FOR LEE YOUNG You are a student near the end of your fifth and final year of a BSc/BCom (Honours) at University of New South Wales (UNSW). You majored in pharmacology in your science degree and did so well that you did an (additional) honours year and received First Class Honours. You are currently finishing your commerce degree, majoring in International Business where your results are very good. Your first love is scientific research but you are open to working and learning in other fields. You were already mad about science in high school. The main reason you also did a commerce degree was that your careers advisor at high school pointed out that Australia has not been good at providing sufficient, good and secure jobs in science but does much better in providing employment for accountants and those working in the finance industry. Business studies were your insurance policy. Your honours year has given you a real passion for doing further scientific research. You have really enjoyed your time at UNSW and would really like to return there to work on a PhD. However, what you know about the insecurity and unpredictability of university research funding for science in Australia – and hence for employment in universities – has made you wary about going down the traditional research training route: seeking a PhD scholarship (which you would very probably get); then a post-doctoral fellowship; and then an academic position. Once again, your concerns about employment and career security mean that you are seeking to do further scientific research training through another route – employment in a leading “pharma” company. You are now about to negotiate an employment offer package with Alex Reclutamento of Purezza Pharmaceuticals (Asia-Pacific) (PP). PP is an Italian-based multinational company that has been rapidly expanding into the Asia-Pacific region through its regional headquarters in Sydney. You already know a bit about PP as you did an internship there over the last summer break. In fact, Alex was your manager during that summer internship and she helped show you around the Sydney headquarters, research laboratories, production facility and warehouse. However, most of your time involved working with Alex in the commercial side of PP's business. You very much enjoyed your summer experience at PP because the people – particularly Alex – were so helpful and supportive and because it gave you a really good insight into the commercial side of the international pharmaceutical industry. As well, you can see that PP offers satisfying career opportunities, whether you opt to further your interest in pharmacological research or the commercial side of the industry – or, perhaps, both! PP’s expansion into the Asia-Pacific seems exciting, as does its reputation for research-based innovation in pharmaceutical production. The thought of an overseas posting is also very attractive. Finally, you have seen and heard that the company makes a real effort to make employment there attractive. Everything you saw convinced you that PP is a company you would like to work for. The company seemed pleased with your performance and Alex told you, before you finished your internship, that you are one of the top candidates for a permanent job out of the 8 summer interns. Alex also mentioned at the time that PP would probably make offers of full-time positions to no more than about 4 of those summer interns. In early April 2018, shortly after starting back at university, you received a letter with the terms of a job offer. Unfortunately, the overall employment package they propose does not fully satisfy your needs. With PP willing to wait for a decision until August 2, you sat on the offer while pursuing other possible job opportunities during the business school recruiting season. Now it is late July, and you have contacted Alex to discuss the terms of the PP offer. 2 The job-search season has been turned out well for you. In addition to the PP offer, you currently have offers from: i. another European-based multinational pharmaceutical business, Medicait (Australasia) (Medicait). Medicait however specializes in producing and selling a range of popular generic pharmaceuticals into Australia and New Zealand; and ii. a tiny, local venture capital-funded company, Going North Products (GNP). GNP is working, in partnership with a local university research team, towards developing patents on formulae developed at that university. Your primary goal is to find employment in a leading multinational pharma company that will provide you with opportunities: • to further your research career, as well as • to go into the more commercial side of the business, including its international aspects. The way you see it, this should be your first big career job opportunity and it should set up the next stages of your career, which might well include international experience and a management track. In any case, you see yourself committing a number of years to the firm, all things going well. You thus seek an opportunity that will provide a mix of further research education and corporate training, progressive responsibility, and employment security as well as diverse and interesting work. Both PP and Medicait offer particular advantages. PP has the advantage of large-scale, advanced and multinational research capacity through its various laboratories. It also sponsors collaborative research projects at the Politecnico University in Milan, other universities in Europe and the USA and at UNSW. Its commercial presence across Europe and North and South America is impressive and it is now making a major investment in the Asia-Pacific. PP was also recently named one of the top 50 European companies to work for in a major Economist (magazine) survey. The immediate prospects for you at Medicait appear to be better, in some ways, but also narrower. While very successful in commercializing generic drugs, Medicait has a very small independent research capacity. Rather, it has been very successful at manufacturing products from formulae whose patents are no longer in force through passage of time. This suggests that, were you to join Medicait, you would almost certainly be giving up on your scientific aspirations and committing yourself wholly to management or commercial aspects of the business. On the other hand, Going North Products has almost no commercial presence as yet but is working closely with a university to move through clinical stage trials for 5 formulae and towards patents in Australia and abroad. If it is successful in this, it will probably never produce those pharmaceuticals but sell them on very profitably to a multinational pharma “major”. The current management intends to keep the company small, cost-efficient and lean. This is due to the fact that it only has a limited “bucket” of funds from its venture capital partners. At GNP then, there seems to be room for you to work closely with the university group doing that research but little real chance of developing any kind of managerial or international experience. A disappointing aspect of the PP offer is that it does not include any mention of your hoped- for sponsorship (through paying you a salary) for further research training in a full-time PhD (working with your honours supervisor). Informally, Alex had assured you that, within a year or so, you should be able to apply for this kind of scholarship but that PP normally insists that graduate recruits spend some time becoming socialized into the company first. Your friends at PP say that management typically is able to follow through on these kinds of assurances if you perform up to expectations – but doesn’t like to put any such promises in writing. 3 In the meantime, PP has offered you a generic “graduate recruit” position in the section responsible for marketing the firm’s blood-pressure and cholesterol-lowering drugs into North-East Asia. Alex heads that section. The offer from Medicait includes no research career opportunities. Yet, it suggests quicker career progress on the commercial side, including starting as a trainee assistant product manager in business development. From what you have heard, after a year or so, you could become an assistant product manager. The starting salary at Medicait is 5,000 higher than at PP). It comes with a signing-on bonus of 37,600 per annum, tax free. To earn 43,000 per year, before tax, as a regular employee on a salary. Assignment: You are wondering if you should raise with Alex your main disappointment with PP's offer: having to start as a generic graduate recruit rather than in a precise business, scientific management or research role. If only she could upgrade the offer by making the formal role more prestigious than graduate recruit! That would satisfy your aspirations towards developing the business side of your career as well as your belief that you bring much more to the company than a typical graduate recruit. Even better, the company could offer you a precise role on the R&D side. Nonetheless, you realize that Alex knows full well about your career interests and goals, and perhaps there are legitimate reasons why PP offered you the generic title and in that unit. Would raising this issue merely alienate Alex, and therefore make it harder to negotiate other issues? Or is it worth using the fact that the Medicait offer is as a trainee assistant product manager in business development to try to push PP into a change in their offer? Salary/Job Title: From what you can tell from recruitment web sites, a graduate recruit’s annual salary for similar scientific fields sits, depending on degree and results, between 57,800, with potential for up to 62,000. Likely annual increments make more palatable the fact that the starting salary offer does not seem to fully recognize what you bring to the company. You are potentially willing to trade off up to 2,500. Share Options: Given the uncertain short and medium-term outlook for venture capital stocks in the current economy, it is very difficult to assess the value of share options from GNP. At best, you could perhaps use it to ask for more base salary or scholarship support from PP. Start Date: The start date is not a major concern for you, but apparently it is for PP because Alex told you that she is desperate to expand her section as soon as possible. The markets are booming for blood-pressure and cholesterol-lowering drugs in Japan, South Korea and now China as rising standards of living encourage more unhealthy eating habits there. PP is very committed to making major inroads into those markets and Alex has the responsibility to see that it happens. You did mention to Alex some time ago that you and your fiancé` were planning on travelling around Europe – and particularly Italy! – for a few months after finishing up your studies in November. However, in reality, plans for the trip are tentative at best right now. You could use this issue to gain some concessions on other issues. In summary, PP is your first choice as a place to work among the set of offers that you have received. Medicait is your obvious second choice, and certainly a very acceptable alternative, if you are prepared to forgo your research career. Still, you feel you need to see some non-trivial improvements in the terms of employment offered before you are willing to choose PP over Medicait.
As part of the preparation for this negotiation, prepare chit chat question to ask Alex in order to gain information that would be useful to improve your negotiating position.
- Assistant
-
Hi Alex, it's great to speak with you again! I was just wondering, how has the company been performing lately in terms of overall growth and expansion into Asia Pacific region?
-
Alex, you have worked at PP for a quite a while now, can you share some of your personal experiences related to career growth and international opportunities within the company?
-
I remember you mentioned that there has been an urgent need to expand the team in your section. Can you share some more details about the upcoming projects and the additional responsibilities that might come with them?
-
What has been your experience regarding annual bonuses and performance-based incentives at PP? Are there any specific criteria or milestones that the company looks for before awarding bonuses?
-
I'm curious about PP's perspective on employee professional development and training opportunities. How does the company support employees who are interested in pursuing further education or skill development?
-
Alex, can you share any recent success stories of employees who were able to transition from one department to another, particularly from the commercial side to the R&D side?
-
As a multinational company, what are the chances for someone like me to have the opportunity to work in one of PP's overseas locations or collaborate with international teams?
-
How does PP usually handle cases where employees express interest in pursuing a PhD while maintaining their roles in the company? Are there any examples of employees who have successfully done so, and what kind of support did the company provide in those cases?
-
- User
Summarise the estimated perceptions and understandings of the situation
- Assistant
Lee Young, a final year undergraduate student, has received a job offer from Purezza Pharmaceuticals (PP) and is currently evaluating his options. His main career interest lies in scientific research, with a desire to pursue a PhD while working at a leading pharmaceutical company. Lee has previously completed an internship at PP in the commercial side of the business, where he worked under Alex Reclutamento.
Lee has three job offers on the table: one from PP, one from another European-based pharmaceutical company, Medicait, and one from a small local venture-funded company, Going North Products (GNP). PP is Lee's preferred choice due to its worldwide research capacity, expansion into Asia-Pacific, and reputation for being an excellent employer.
However, there are several concerns Lee has with PP's offer, such as the generic graduate role and the starting salary. Lee is pondering whether to negotiate the offer terms by leveraging other job offers and highlighting his academic qualifications. He also hopes to secure PP's support for pursuing a PhD alongside his employment.
In his upcoming conversation with Alex, Lee aims to gain a better understanding of PP's performance, career growth opportunities, international projects, bonus systems, professional development support, examples of successful transitions within the company, and possibilities of working in overseas locations. He hopes to use this information to advocate for an improved job offer from PP before making his final decision.